- Home
- GLPG vs BCRX Comparison
GLPG vs BCRX Comparison
Compare GLPG & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- BCRX
- Stock Information
- Founded
- GLPG 1999
- BCRX 1986
- Country
- GLPG Belgium
- BCRX United States
- Employees
- GLPG N/A
- BCRX N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLPG Health Care
- BCRX Health Care
- Exchange
- GLPG Nasdaq
- BCRX Nasdaq
- Market Cap
- GLPG 2.1B
- BCRX 1.8B
- IPO Year
- GLPG 2005
- BCRX 1994
- Fundamental
- Price
- GLPG $31.44
- BCRX $8.39
- Analyst Decision
- GLPG Sell
- BCRX Strong Buy
- Analyst Count
- GLPG 4
- BCRX 10
- Target Price
- GLPG $25.33
- BCRX $16.70
- AVG Volume (30 Days)
- GLPG 345.0K
- BCRX 3.2M
- Earning Date
- GLPG 07-23-2025
- BCRX 08-04-2025
- Dividend Yield
- GLPG N/A
- BCRX N/A
- EPS Growth
- GLPG N/A
- BCRX N/A
- EPS
- GLPG N/A
- BCRX N/A
- Revenue
- GLPG $323,674,692.00
- BCRX $557,506,000.00
- Revenue This Year
- GLPG N/A
- BCRX $41.37
- Revenue Next Year
- GLPG N/A
- BCRX $7.56
- P/E Ratio
- GLPG N/A
- BCRX N/A
- Revenue Growth
- GLPG 5.43
- BCRX 45.85
- 52 Week Low
- GLPG $22.36
- BCRX $6.02
- 52 Week High
- GLPG $33.86
- BCRX $11.31
- Technical
- Relative Strength Index (RSI)
- GLPG 47.00
- BCRX 46.66
- Support Level
- GLPG $31.39
- BCRX $8.18
- Resistance Level
- GLPG $32.43
- BCRX $8.62
- Average True Range (ATR)
- GLPG 0.77
- BCRX 0.22
- MACD
- GLPG -0.22
- BCRX 0.05
- Stochastic Oscillator
- GLPG 7.22
- BCRX 54.39
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.